The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro

Browse by...

Deposit

Highlights

More informations

Title		The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro
Authors		Ancrenaz, Virginie Desmeules, Jules Alexandre James, Richard William Fontana, Pierre Reny, Jean-Luc Dayer, Pierre Daali, Youssef
Published in		British Journal of Pharmacology. 2012, vol. 166, no. 8, p. 2362-70
Abstract		Clopidogrel is a prodrug bioactivated by cytochrome P450s (CYPs). More recently, paraoxonase-1 (PON1) has been proposed as a major contributor to clopidogrel metabolism. The purpose of this study was to assess the relative contribution of CYPs and PON1 to clopidogrel metabolism in vitro.
Identifiers		DOI: 10.1111/j.1476-5381.2012.01946.x PMID: 22428615
Full text		Article (Published version) (1 MB) - Limited access to UNIGE
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine Faculté de médecine / Section de médecine clinique / Département d'anesthésiologie, pharmacologie, soins intensifs et urgences Faculté des sciences / Section des sciences pharmaceutiques
Research groups		Pharmaco-omiques et médecine de précision (1003) Geneva Platelet Group (13) Groupe Desmeules Jules (pharmacologie/toxicologie) (567)
Citation (ISO format)		ANCRENAZ, Virginie et al. The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro. In: British Journal of Pharmacology, 2012, vol. 166, n° 8, p. 2362-70. doi: 10.1111/j.1476-5381.2012.01946.x https://archive-ouverte.unige.ch/unige:26343